Of note, a key differentiator between other approaches, such as NMNAT1 and SIRT-1 gene therapies, which also modulate mitochondrial dysfunction, and the therapeutic strategy for glaucoma demonstrated in the current study, is that eNdi1, as a complex I equivalent, directly participates in the electron transport chain. The gene discussed is SIRT1; the disease is glaucoma.